Standard Operating Procedure: Consumer Case Referral Onboarding (MAS)

This Standard Operating Procedure (SOP) outlines the mandatory workflow for receiving, validating, and onboarding consumer case referrals into the Managed Access Services (MAS) ecosystem. The objective of this protocol is to ensure data integrity, maintain regulatory compliance, and guarantee a seamless transition for the consumer from the point of referral to program enrollment. Adherence to these steps is critical to minimizing processing delays and ensuring that patient support services are initiated without friction.

Phase 1: Intake and Data Verification

• Referral Receipt: Confirm receipt of the referral via the designated secure transmission channel (e.g., encrypted email, portal, or fax).
• Completeness Check: Verify that all mandatory fields are populated, including consumer demographics, prescribing physician information, and diagnosis codes.
• Authorization Verification: Ensure the consumer’s HIPAA/Data Privacy Authorization is attached and signed. If missing, flag as "Pending – Action Required."
• Duplicate Check: Query the CRM/MAS database to ensure the consumer does not already exist as an active or closed record to prevent duplicate profiles.

Phase 2: Eligibility and Benefit Investigation

• Payer Identification: Determine the primary, secondary, and tertiary insurance coverage based on provided documentation.
• Plan Validation: Perform an electronic benefit verification (eBV) to confirm active coverage and identify specific formulary requirements.
• Prior Authorization (PA) Audit: Assess if the prescribed therapy requires a PA. If yes, log the initiation date and notify the prescribing office immediately.
• Financial Assistance Screening: Evaluate the consumer against program criteria for co-pay assistance, bridge programs, or patient assistance programs (PAP).

Phase 3: Consumer Outreach and Enrollment

• Welcome Communication: Execute the initial welcome call/email within the established SLA (e.g., 24-48 business hours).
• Program Orientation: Clearly explain the MAS services, privacy protections, and expectations for ongoing communication.
• Consent Confirmation: Verbally verify or obtain digital consent for program participation and data sharing.
• Final Profile Update: Input all gathered information into the MAS platform and transition the case status from "Referral" to "Enrolled/Active."

Pro Tips & Pitfalls

• Pro Tip – The "Golden Hour": Reach out to the consumer within the first 4 hours of receipt. Conversion rates for program engagement drop significantly after the first 24 hours of inactivity.
• Pro Tip – Pre-Emptive PA Outreach: Do not wait for the denial to initiate a Prior Authorization. If the system flags a likelihood of denial based on payer history, send the PA template to the physician’s office during the intake phase.
• Pitfall – Stale Data: Never assume patient contact information provided by the referral source is current. Always use a third-party verification tool to confirm the phone number and address before the first attempt.
• Pitfall – Privacy Breaches: Ensure all referral documents are stored in the secure MAS environment. Never save referral attachments locally on your desktop or unencrypted cloud folders.

Frequently Asked Questions (FAQ)

Q: What should I do if a referral is missing a signature on the HIPAA authorization? A: You must immediately place the case in a "Pending" status and notify the referral source via secure portal messaging. Do not perform any outreach or data processing on the consumer until the signed document is received.

Q: How do I handle a case where the consumer has no insurance? A: Follow the "Uninsured Workflow." Immediately pivot the case to the PAP (Patient Assistance Program) track to assess eligibility for manufacturer-sponsored drug programs.

Q: Is it acceptable to leave a voicemail for a consumer on the first attempt? A: Yes, but you must strictly adhere to the "Minimum Necessary" standard. State your name, the name of your organization, and a secure call-back number. Do not disclose the specific drug name or diagnosis in the voicemail to protect consumer privacy.